Feb 16, 2021
A new study shows that the less-invasive saliva test for COVID-19 gives just as accurate results as those of the nasopharyngeal specimen.
A research team at the Department of Laboratory Medicine at Kangwon National University School of Medicine, led by Professor In-bum Suh, carried out the PCR test for COVID-19 on 90 hospitalized individuals with suspected COVID-19, both with saliva and nasopharyngeal methods. In order to collect sufficient specimen, samples were collected from study participants, who were required to refrain from any activities including eating, drinking, and smoking, for 30 minutes after they got up in the morning.
For the study, the research team had used Seegene's flagship COVID-19 tests, 'Allplex™ SARS-CoV-2 Assay' and 'Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay, both of which had been CE-IVD marked. While 'Allplex™ SARS-CoV-2 Assay' targets 4 different genes of COVID-19, 'Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay' is known to detect and differentiate 8 target genes including COVID-19, influenza and RSV common cold.
As a result, both 'Allplex™ SARS-CoV-2 Assay' and 'Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay' proved the saliva and nasopharyngeal test's percentage agreement for detecting COVID-19 was over 98.8%. That means Seegene's COVID-19 diagnostic test gives equally accurate and effective test results for COVID-19 when testing saliva and nasopharyngeal specimen.
Professor Suh, the lead researcher of the study said, "The demand for saliva-based COVID-19 tests is on the rise, as the world still battles with short supply of specimen collecting swab for nasopharyngeal tests." He added that the study has "clearly proven that saliva tests are just as accurate and effective as nasopharyngeal tests in precisely diagnosing COVID-19."
The research team also conducted a separate study on extraction-free application, one without the nucleic acid extraction step, and found the percentage agreement between Seegene's extraction-free saliva test and extraction-free nasopharyngeal swab test to be over 96%. In other words, the extraction-free method using the saliva sampling would be just as applicable for the PCR test in detecting SARS-CoV-2.
Generally in COVID-19 PCR tests, the nucleic acid extraction process is considered as a prerequisite in order to isolate and purify nucleic acid from specimens. Depending on the circumstances, however, some countries may not be fully equipped to carry out the extraction process. Some even face reagent shortages, despite a surge in testing capacity, eventually leading many laboratories to resort to extraction-free method.
The implication of the study will be introduced during the 28th International Molecular Medicine Tri-Conference. The three-day conference will be held online due to COVID-19 pandemic starting February 16th. The Molecular Medicine Tri-Conference is one of the leading international meeting places for the precision medicine community, where leaders are invited to discuss the latest research and technologies in COVID-19 diagnostics and bio therapeutics.
- Seegene’s new product filters COVID-19 and variants during primary PCR testing in 1 hr 55 min - Seegene’s proprietary high multiplex technology enables detection of 10 different targets - S. Korean firm to research additional versions of variant diagnostic tests Seegene (KQ096530), a bi...
- SEEGENE ROLLS OUT FIRST COVID-19 MUTANT IDENTIFICATION TEST - COVID-19 TEST MANUFACTURER CONTINUES TRACKING VARIANTS - S. KOREAN FIRM COMMITTED TO WORKING WITH GOVERNMENTS South Korea’s biotechnology firm Seegene (KQ096530) said Monday it developed the world’s first COVID-19 diagnosti...